What is Alpha Teknova, Inc.'s (TKNO) StockRank?

MoatMap's StockRank for Alpha Teknova, Inc. (TKNO) is 32/100, with a Sell signal. This is a composite score combining Quality (37), Value (27), and Momentum (58) factor ranks across MoatMap's 20,000+ stock universe.

Does Alpha Teknova, Inc. have an economic moat?

Alpha Teknova, Inc. (TKNO) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Alpha Teknova, Inc. a buy, hold, or sell?

MoatMap's current signal for Alpha Teknova, Inc. (TKNO) is Sell, based on a StockRank of 32/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Alpha Teknova, Inc. in?

Alpha Teknova, Inc. (TKNO) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

TKNO

SELLREMOVE

Alpha Teknova, Inc. · Healthcare · United States · $272M · Avg Vol: $1M/d

StockRank

P/E (TTM)

—

ROE

-23.9%

D/E

0.4x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Alpha Teknova provides reagents for bioprocessing but lacks the scale, profitability, and market dominance required to play the CDMO or advanced therapeutics theme effectively.

COMPANY DESCRIPTION

Alpha Teknova, Inc. is a leading provider of validated, research-grade reagents for life sciences applications, including genomics, proteomics, and cell culture. The company offers a broad portfolio of media, buffers, and other solutions essential for pharmaceutical and biotech R&D, as well as clinical diagnostics. Teknova holds a strong niche market position as a critical supplier of high-quality, custom-formulated reagents, supporting the accelerated pace of scientific discovery and biopharmaceutical development.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	41.4M	36.7M	37.7M	40.5M	-0.7%
EPS	-1.69	-1.16	-0.57	-0.32	—
Shares	28.2M	40.8M	53.4M	53.6M	+90.1%
Debt	42.3M	30.5M	30.2M	28.3M	-12.6%
Equity	99.9M	90.0M	82.4M	68.8M	-11.7%
Op CF	-27.4M	-18.8M	-12.4M	-8.6M	—
Inv CF	-28.1M	-7.7M	-27.3M	10.7M	—
Fin CF	10.3M	12.8M	14.9M	0.2M	—

PRICE (1Y)+30.3%

SMA 50SMA 200

$5.20

RSI (14)

51.0

52W High

$6.68

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-17.2%29.7

ROE

-23.9%28.5

GP/Assets

13.7%32.8

Op. Margin

-38.8%22.5

FCF/Assets

-2.3%43.0

Piotroski

549.0

Int. Cover

-23.2x17.4

D/E Ratio

0.43x35.3

Current Ratio

4.59x68.0

Value

P/E (TTM)

—N/A

EV/EBITDA

-30.7x25.0

P/FCF

—N/A

P/B

4.1x31.7

P/S

6.3x34.7

Div Yield

—N/A

Momentum

52W High %

78%71.0

RS 6M

4%78.3

SMA 50/200

1.01x58.0

EPS Rev 4W

0.0%49.2

EPS Rev 12W

+23.9%79.2

EPS Improve

+21%34.0

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$272M

P/E (Forward)

-20.2x

Gross Margin

34.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TKNO are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
TKNO	Alpha Teknova, Inc.(you)	$272M	32	SELL
CL.CN	Cresco Labs Inc.	$293M	31	SELL
ORGO	Organogenesis Holdings Inc.	$309M	31	SELL
EOLS	Evolus, Inc.	$432M	32	SELL
AKBA	Akebia Therapeutics, Inc.	$299M	18	STRONG SELL
VREO.CN	Vireo Growth Inc.	$532M	28	SELL
DERM	Journey Medical Corporation	$180M	19	STRONG SELL
ESPR	Esperion Therapeutics, Inc.	$814M	30	SELL
LFCR	Lifecore Biomedical, Inc.	$207M	10	STRONG SELL
CWEB.TO	Charlotte's Web Holdings, Inc.	$74M	30	SELL

Peer medians: ROE -23.1% · P/E 25.2x · Gross margin 44.3%

Alpha Teknova, Inc. (TKNO) — Stock Score Summary

Alpha Teknova, Inc. (TKNO) has a MoatMap StockRank of 32/100 based on Quality (37/100), Value (27/100), and Momentum (58/100) factor scores. The current signal is SELL. Alpha Teknova provides reagents for bioprocessing but lacks the scale, profitability, and market dominance required to play the CDMO or advanced therapeutics theme effectively.

Key Financial Metrics

Price	$5.20
Market Cap	$272M
P/E (Forward)	-20.17
Price/Book	4.08
Return on Equity	-23.9%
Return on Invested Capital	-17.2%
Debt/Equity	42.86
Gross Margin	34.0%
Operating Margin	-38.8%
Revenue Growth	13.1%
Free Cash Flow	$-2M

Alpha Teknova, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Alpha Teknova, Inc.’s (TKNO) StockRank?: MoatMap’s StockRank for Alpha Teknova, Inc. (TKNO) is 32/100, with a Sell signal. It is a composite of Quality (37), Value (27), and Momentum (58) factor ranks across MoatMap’s 20,000+ stock universe.
Does Alpha Teknova, Inc. have an economic moat?: Alpha Teknova, Inc. (TKNO) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Alpha Teknova, Inc. a buy, hold, or sell?: MoatMap’s current signal for Alpha Teknova, Inc. (TKNO) is Sell, based on a StockRank of 32/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Alpha Teknova, Inc. in?: Alpha Teknova, Inc. (TKNO) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).